Overview

Carboplatin And Paclitaxel With Or Without CP-751, 871 (An IGF-1R Inhibitor) For Advanced NSCLC Of Squamous, Large Cell And Adenosquamous Carcinoma Histology

Status:
Terminated

Trial end date:
2012-09-01

Target enrollment:

Participant gender:

Summary

Determine whether the addition of CP- 751,871 in combination with paclitaxel plus carboplatin prolongs survival in patients with locally advanced (Stage IIIB with pleural effusion) or metastatic (Stage IV or recurrent) NSCLC of non adenocarcinoma histology.

Phase:

Phase 3

Details

Lead Sponsor:

Pfizer

Treatments:

Albumin-Bound Paclitaxel
Carboplatin
Paclitaxel